Abstract:Tuberculosis (TB) remains a global health threat of alarming proportions, resulting in 1.5 million deaths worldwide. The only available licensed vaccine, Bacillus Calmette-Guérin, does not confer lifelong protection against active TB. To date, development of an effective vaccine against TB has proven to be elusive, and devising newer approaches for improved vaccination outcomes is an essential goal. Insights gained over the last several years have revealed multiple mechanisms of immune manipulation by Mycobacterium tuberculosis (Mtb) in infected macrophages and dendritic cells that support disease progression and block development of protective immunity. This review provides an assessment of the known immunoregulatory mechanisms altered by Mtb, and how new interventions may reverse these effects. Examples include blocking of inhibitory immune cell coreceptor checkpoints (e.g., programed death-1). Conversely, immune mechanisms that strengthen immune cell effector functions may be enhanced by interventions, including stimulatory immune cell coreceptors (e.g., OX40). Modification of the activity of key cell "immunometabolism" signaling pathway molecules, including mechanistic target of rapamycin, glycogen synthase kinase-3β, wnt/β-catenin, adenosine monophosophate-activated protein kinase, and sirtuins, related epigenetic changes, and preventing induction of immune regulatory cells (e.g., regulatory T cells, myeloid-derived suppressor cells) are powerful new approaches to improve vaccine responses. Interventions to favorably modulate these components have been studied primarily in oncology to induce efficient antitumor immune responses, often by potentiation of cancer vaccines. These agents include antibodies and a rapidly increasing number of small molecule drug classes that have contributed to the dramatic immune-based advances in treatment of cancer and other diseases. Because immune responses to malignancies and to Mtb share many similar mechanisms, studies to improve TB vaccine responses using interventions based on "immuno-oncology" are needed to guide possible repurposing. Understanding the regulation of immune cell functions appropriated by Mtb to promote the imbalance between protective and pathogenic immune responses may guide the development of innovative drug-based adjunct approaches to substantially enhance the clinical efficacy of TB vaccines.

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Single-Dose Mucosal Immunotherapy with Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound after Antibiotic Cessation

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.

Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity

Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses

Nanomaterials in Tuberculosis DNA Vaccine Delivery: Historical Perspective and Current Landscape

Promising Cytokine Adjuvants for Enhancing Tuberculosis Vaccine Immunity

Advance in strategies to build efficient vaccines against tuberculosis

Applications of Nanomaterials As Vaccine Adjuvants

Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Adjuvant physiochemistry and advanced nanotechnology for vaccine development

Self-Adjuvanting Adenoviral Nanovaccine for Effective T-Cell-Mediated Immunity and Long-Lasting Memory Cell Activation against Tuberculosis

Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

Promotion of Th17 Polarized Immunity via Co-Delivery of Mincle Agonist and Tuberculosis Antigen Using Silica Nanoparticles

Nanomaterial-Based Vaccine Adjuvants.

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis

Applications and Perspectives of Nanomaterials in Novel Vaccine Development

Advanced technologies for the development of infectious disease vaccines